ClinicalTrials.gg
CompletedNCT05859529Updated Sep 5, 2024

A Pharmacokinetic Study of JS002 in Healthy Subjects

A Phase 1 interventional study of JS002 in Health Volunteer, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study was a single-center, randomized, open-label, single-dose, parallel-controlled trial design conducted in healthy adult subjects. Subjects were randomly assigned to 1 of 2 parallel treatment groups: treatment group A received a single subcutaneous injection of JS002 150 mg via PFS, and treatment group B received a single subcutaneous injection of JS002 150 mg via AI. Subjects were followed up to study day 85 for pharmacokinetic equivalence assessment of JS002. A total of 159 subjects were planned to be included in each group. After signing the informed consent form and completing the screening examination, subjects will be randomly assigned to treatment arm A or treatment arm B if eligible for inclusion.

The study period consisted of a screening period of up to 21 days and a follow-up period of 12 weeks (85 days). Subjects were admitted to the phase I clinical research unit the day before dose administration (day 1) and were not allowed to leave until all examinations and assessments were completed on day 6 after dose administration and were allowed to return to the clinical research center for follow-up visits on days 8,11,15,22,29,43,57,71, and 85.

02

Conditions studied

  • Health Volunteer
03

In context

Lead sponsor

Shanghai Junshi Bioscience Co., Ltd. is the lead sponsor of 100 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female volunteers aged 18-45 years at screening;
  2. have the ability to read and understand, voluntarily participate in the study, sign the written , and be able to complete the relevant procedures and examinations in accordance with the protocol;
  3. the (BMI) at screening ranged from 19 to 26 kg/m2 (inclusive), with body weight ≥50kg for men and ≥45kg for women;
  4. sitting blood pressure ≥ 90/60mmHg and \< 140/90mmHg during screening;
  5. serum LDL-C level ≥1.8mmol/L and \< 4.9mmol/L at screening;
  6. serum TG level \< 2.8mmol/L at screening;
  7. infertile, or fertile women willing to use strict and effective methods throughout the study, in addition, fertile female subjects should have negative blood pregnancy test results during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Any history of use of Evolocumab and/or Alirocumab and other targeted drugs against PCSK9;
  2. Use of any therapeutic or biologics within 6 months before baseline (day 1);
  3. Use of any medications or supplements that can alter blood lipids or affect lipid metabolism within 30 days before baseline (day 1), including but not limited to: Statins (such as atorvastatin, rosuvastatin, etc.), cholesterol absorption inhibitors (such as ezetimibe), probucol, cholic acid chelators (such as cholestyramine), traditional Chinese medicine (such as Xuezhikang), fibrates, high-purity fish oil preparations (or omega-3 fatty acids 1000 mg/ day), niacin preparations (niacin > 50 mg), etc.
  4. Initiation of new vigorous exercise (e.g., long-distance running) or dietary control, or major modification of previous diet or lifestyle (e.g., exercise, smoking, and alcohol consumption) within 30 days before baseline (day 1). Creatine kinase (CK) ≥3 times the value (ULN) on the day before randomization (day-1);
  5. A history of allergy to biologics of mammalian origin (including monoclonal antibodies);
  6. Subjects with allergic diseases or allergic constitution;
  7. Patients with definite diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, endocrine system, and metabolic system that require medical intervention or other diseases that are not suitable for clinical trial (such as psychiatric history);
  8. Donating ≥400 mL within 3 months before screening, or donating ≥200 mL within 1 month before screening, or receiving blood transfusion;
  9. Participants who participated in other drug clinical trials within 3 months before screening;
  10. Those who had taken any prescription drugs, over-the-counter drugs, herbal medicines, or health supplements within 2 weeks before screening;
  11. Heavy smokers and drinkers (drinking 14 units of alcohol per week:1unit = beer 360 mL, or liquor 45 mL, or wine 150 mL; Smoking ≥5 cigarettes per day), or unable to abstain from smoking or drinking alcohol during the study period;
  12. Had a history of drug abuse, or used drugs within 3 months before screening, or had a positive urine drug screening test during the screening period;
  13. surface antigen (HBsAg), virus antibody (Anti-HCV), treponema pallidum antibody and acquired immunodeficiency syndrome () antibody positive;
  14. Abnormal chest X-ray (posterior-anterior view) and abdominal B-ultrasound results with clinical significance (non- conditions such as irritability of gallbladder wall, hepatic cysts, intrahepatic calcifications, intrahepatic bile duct stones, slight fatty liver, etc., should be excluded).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Experimental:JS002 AI

    The drug was administered by a single subcutaneous injection via AI

    Drug: JS002

  • Active comparator
    Experimental:JS002 PFS

    The drug was administered by a single subcutaneous injection via PFS

    Drug: JS002

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-last

    Area under the time-concentration curve from time 0 to last time of quantifiable concentration

    Time frame: 85 days

  2. Cmax

    Maximum Concentration

    Time frame: 85 days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in physical examination, vital signs, electrocardiogram, laboratory tests.

    Time frame: 85 days

  2. Tmax

    Time to reach maximum concentration

    Time frame: 85 days

  3. t1/2

    Elimination half life

    Time frame: 85 days

  4. CL/F

    Apparent clearance

    Time frame: 85 days

  5. Vz/F

    Apparent volume of distribution

    Time frame: 85 days

  6. AUECday1-85

    Area under the effect curve (AUEC) for LDL-C through Day 1 to day 85

    Time frame: 85 days

  7. PCSK9

    Serum concentration of PCSK9

    Time frame: 85 days

  8. Immunogenicity

    Incidence of antidrug antibodies (ADA)

    Time frame: 85 days

  9. Immunogenicity

    Titer of ADA-positive samples, and incidence of neutralizing antibodies (Nab)

    Time frame: 85 days

07

Study locations

1 site
  • Shenzhen Third People's Hospital
    Shenzhen, Guangdong 518112, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jun 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2023
First posted
May 16, 2023
StartActual
May 30, 2023
Primary completionActual
Jun 30, 2023
CompletionActual
Sep 11, 2023
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05859529
Collaborators
Sponsor GmbH
Responsible party
Sponsor
First posted
May 16, 2023
Start date
May 30, 2023
Primary completion
Jun 30, 2023
Completion
Sep 11, 2023
Last update
Sep 5, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion